FINAL PROGRAM - Society for Immunotherapy of Cancer
FINAL PROGRAM - Society for Immunotherapy of Cancer
FINAL PROGRAM - Society for Immunotherapy of Cancer
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Poster Listings<br />
134<br />
COMBINED THERAPY WITH V 9V 2 T CELLS AND<br />
ZOLEDRONATE IN PATIENTS WITH ADVANCED<br />
SOLID TUMORS<br />
Andrew Nicol, Mie Nieda, Tomomi Hagi, Jennifer Nicol, Aniruddha<br />
Choudhury<br />
University <strong>of</strong> Queensland, Brisbane, QLD, Australia<br />
135<br />
DENDRITIC CELLSTRANSFECTED WITH ERBB-<br />
2 RAT/HUMAN HYBRID PLASMID ELICIT AN<br />
EFFECTIVET CELLS RESPONSE IN ERBB2+ CANCER<br />
PATIENTS<br />
Sergio Occhipinti 1 , Laura Sponton 1 , Cristiana Caorsi 1 , Augusto Amici 2 ,<br />
Cristina Marchini 2 , Elena Quaglino 3 , Anna Novarino 4 , Michela<br />
Donadio 4 , Libero Ciuffreda 4 , Francesco Novelli 1 , Mirella Giovarelli 1<br />
1<br />
Department <strong>of</strong> Medicine and Experimental Oncology, University <strong>of</strong><br />
Turin, Turin, Italy<br />
2<br />
Department <strong>of</strong> Molecular Cellular and Animal Biology, University <strong>of</strong><br />
Camerino, Camerino, Italy<br />
3<br />
Molecular Biotechnology Center, University <strong>of</strong> Turin, Turin, Italy<br />
4<br />
C.O.E.S. Subalpine OncoHematology <strong>Cancer</strong> Center, San Giovanni<br />
Battista Hospital, Turin, Italy<br />
136<br />
CISH DEGRADATION OF HTRA1 REGULATESTGF-<br />
SIGNALING<br />
Douglas C. Palmer, Robert N. Reger, Lindsay M. Garvin, Dorina<br />
Frasheri, Yun Ji, Zulmarie J. Franco, Christopher A. Kleban<strong>of</strong>f, Luca<br />
Gattinoni, Nicholas P. Restifo<br />
NCI, National <strong>Cancer</strong> Institute, Bethesda, MD<br />
137<br />
CANCERTESTIS ANTIGENS AS PROGNOSTIC<br />
BIOMARKERS FOR BREAST CANCER PATIENTS<br />
Kyle K. Payne 1 , Amir A. Toor 2 , Masoud H. Manjili 1<br />
1<br />
Microbiology & Immunology, Virginia Commonwealth University -<br />
Massey <strong>Cancer</strong> Center, Richmond, VA<br />
2<br />
Internal Medicine, Virginia Commonwealth University - Massey <strong>Cancer</strong><br />
Center, Richmond, VA<br />
138<br />
PHASE I CLINICAL TRIALS IN CANCER<br />
VACCINE DEVELOPMENT DO NOT DETERMINE<br />
DOSE NEITHER BASED ON SAFETY NOR ON<br />
BIOLOGICAL ACTIVITY<br />
Osama Rahma, Emily Gammoh, Richard Simon, Khleif N. Samir<br />
National <strong>Cancer</strong> Institute, Bethesda, MD<br />
139<br />
INFLUENCE OF MELANOMA HOST CELL FACTORS<br />
ON REPLICATION AND EARLY GENE EXPRESSION<br />
OF ONCOLYTIC VACCINIA VIRUS ISOLATES<br />
Jennifer Reinboth 1,2 , Nanhai G. Chen 1 , Qian Zhang 1 , Yong A. Yu 1 , Maria<br />
L. Ascierto 2 , Ena Wang 2 , Francesco M. Marincola 2 , Aladar A. Szalay 1<br />
1<br />
Genelux Corporation, San Diego Science Center, San Diego, CA<br />
2<br />
Immunogenetics Lab, National Institutes <strong>of</strong> Health, Bethesda, MD<br />
140<br />
CALORIC RESTRICTION RESPONSES CAN<br />
MAINTAIN OX40-MEDIATED IMMUNE RESPONSES<br />
DURING AGING<br />
Carl Ruby 1,2,3 , Hugo Jimenez 3 , Mohammed Sanshal 3 , Lana Chisholm 4 ,<br />
Lisa Lukaesko 4 , Andrew Weinberg 4 , Howard Kaufman 1,2,3<br />
1<br />
General Surgery, Rush University Medical Center, Chicago, IL<br />
2<br />
Immunology/Microbiology, Rush University Medical Center, Chicago, IL<br />
3<br />
<strong>Cancer</strong> Center, Rush University Medical Center, Chicago, IL<br />
4<br />
Earle A Chiles Research Institute, Providence Portland Medical Center,<br />
Portland, OR<br />
141<br />
IDENTIFICATION OF PREDICTIVE BIOMARKERS IN<br />
CANCER PATIENTS RECEIVING PERSONALIZED<br />
PEPTIDE VACCINATION<br />
Tetsuro Sasada 1 , Satoko Matsueda 1 , Shigeki Shichijo 1 , Tetsuya Ioji 1 ,<br />
Nobukazu Komatsu 1 , Masanori Noguchi 2 , Akira Yamada 2 , Kyogo<br />
Itoh 1<br />
1<br />
Department <strong>of</strong> Immunology and <strong>Immunotherapy</strong>, Kurume University<br />
School <strong>of</strong> Medicine, Kurume, Japan<br />
2<br />
Research Center <strong>of</strong> Innovative <strong>Cancer</strong> Therapy, Kurume University,<br />
Kurume, Japan<br />
142<br />
VACCINATION WITH THE HER2-DERIVED E75<br />
PEPTIDE VACCINE IN BREAST CANCER PATIENTS<br />
MAY CONFER GREATER BENEFITTO PATIENTS<br />
WITH LESS AGGRESSIVE DISEASE<br />
Alan K. Sears 1 , Guy T. Clifton 1 , Timothy J. Vreeland 1 , Diane F. Hale 1 ,<br />
Jarrod P. Holmes 2 , Ritesh Patil 3 , Sathibalan Ponniah 4 , Elizabeth A.<br />
Mittendorf 5 , George E. Peoples 1<br />
1<br />
Brooke Army Medical Center, Fort Sam Houston, TX<br />
2<br />
Naval Medical Center, San Diego, San Diego, CA<br />
3<br />
Roswell Park <strong>Cancer</strong> Institute, Buffalo, NY<br />
4<br />
<strong>Cancer</strong> Vaccine Development Laboratory, Bethesda, MD<br />
5<br />
MD Anderson <strong>Cancer</strong> Center, Houston, TX<br />
143<br />
COMPARISON OFTKI MEDIATED EFFECTS ONTHE<br />
MECHANISM OFT CELL ACTIVATION<br />
Barbara Seliger, Jana Kalich, Franziska Leich<br />
Martin Luther University, Institute <strong>of</strong> Medical Immunology, Halle,<br />
Germany<br />
72<br />
<strong>FINAL</strong> <strong>PROGRAM</strong> • SITC 26 TH ANNUAL MEETING<br />
November 4-6, 2011 • North Bethesda, MD • www.sitcancer.org
Change language